• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

    11/14/23 5:25:00 PM ET
    $ASH
    $MRK
    Specialty Chemicals
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASH alert in real time by email

    WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023.  Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India.

    As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annual Stockholders Meeting in January 2024. With the addition of Chattopadhyay, Ashland temporarily increases the size of the Board to 11 members until the next Annual Stockholders Meeting in January 2024.

    Chattopadhyay is a broadly experienced global executive who brings strong industry leadership in manufacturing, distribution, supply chain, and more. He has led complex operations that span 22 countries including cutting-edge manufacturing technology while successfully navigating the ever-changing, globally complex, and heavily regulated industry of biopharmaceuticals.

    "I am pleased to welcome Sanat as a new director to the Ashland Board," said Guillermo Novo, chair and chief executive officer, Ashland. "As we continue to execute our strategy and increase our focus and scale in pharmaceuticals, personal care and coatings, I am confident Sanat will provide important perspectives for our team. And once again, I want to thank Jay and Brendan for their dedicated service to the Board."

    To learn more, visit investor.ashland.com

    About Ashland 

    Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environment, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 3,800 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more. 

    ™ Trademark, Ashland or its subsidiaries, registered in various countries.

    FOR FURTHER INFORMATION:

    Investor Relations:Media Relations:
    Seth A. MrozekCarolmarie C. Brown
    +1 (302) 594-5010+1 (302) 995-3158
    [email protected][email protected]

    Attachment

    • Ashland_announces_new_board_member_20231114


    Primary Logo

    Get the next $ASH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASH
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    1/8/2026$135.00Peer Perform → Outperform
    Wolfe Research
    Merck & Company Inc.
    $MRK
    12/18/2025$130.00Market Perform → Outperform
    BMO Capital Markets
    Ashland Inc.
    $ASH
    12/15/2025$71.00Market Perform → Outperform
    BMO Capital Markets
    Merck & Company Inc.
    $MRK
    11/24/2025$125.00Equal Weight → Overweight
    Wells Fargo
    Merck & Company Inc.
    $MRK
    11/13/2025$105.00Sector Outperform
    Scotiabank
    Merck & Company Inc.
    $MRK
    10/13/2025$95.00Neutral
    Citigroup
    Merck & Company Inc.
    $MRK
    9/17/2025$90.00Buy → Hold
    Berenberg
    Ashland Inc.
    $ASH
    9/8/2025$60.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $ASH
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chair of the Board and CEO Novo Guillermo bought $2,010,327 worth of shares (31,294 units at $64.24) (SEC Form 4)

    4 - ASHLAND INC. (0001674862) (Issuer)

    2/3/25 4:30:05 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, General Counsel Zachary Jennifer was granted 11,583 shares, increasing direct ownership by 20% to 68,916 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    1/28/26 4:19:55 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Chief Info&Digital Officer Williams David Michael was granted 6,112 shares, increasing direct ownership by 25% to 30,838 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    1/28/26 4:18:18 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP Fin. - Global Controller Smart Dalton E. Iii was granted 1,066 shares, increasing direct ownership by 11% to 10,605 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    1/28/26 4:16:29 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

    Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX) Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $2.04; GAAP and Non-GAAP EPS Include a Charge of $0.05 per Share for the Acquisition of MK-8690 Sole Global Rights Full-Year Worldwide Sales Were $65.0 Billion (1% Growth; 2% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX Sales Were $31.7 Billion (7% Growth Both Nominally and ex-FX); Includes KEYTRUDA QLEX Sales of $40 Million WINREVAIR Sales Were $1.4 Billion CAPVAXIVE Sales Were $759 Million GARDASIL/GARDASIL 9 Sales Were $5.2 Billion (39% Decli

    2/3/26 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ashland reports first quarter fiscal 2026 results and narrows full-year outlook

    Sales of $386 million, down five percent from the prior-year quarterPreviously announced Avoca divestiture reduced overall sales by approximately $10 million or two percent versus the prior-year quarter; excluding the Avoca divestiture, sales declined three percentLoss from continuing operations of $14 million, or $(0.30) per diluted shareAdjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $12 million, or $0.26 per diluted shareNet loss of $12 million, or $(0.26) per diluted shareAdjusted EBITDA of $58 million, down five percent from the prior-year quarter, with the Avoca divestiture contributing to a two percent or $1 million decline; excluding the Avoca

    2/2/26 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Merck Announces Second-Quarter 2026 Dividend

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the second quarter of 2026. Payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten

    1/27/26 3:07:00 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Merck upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Merck from Peer Perform to Outperform and set a new price target of $135.00

    1/8/26 8:11:51 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Merck from Market Perform to Outperform and set a new price target of $130.00

    12/18/25 8:42:30 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ashland upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded Ashland from Market Perform to Outperform and set a new price target of $71.00

    12/15/25 8:56:16 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    SEC Filings

    View All

    Merck & Company Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Merck & Co., Inc. (0000310158) (Filer)

    2/3/26 6:38:40 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ashland Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ASHLAND INC. (0001674862) (Filer)

    2/2/26 5:11:11 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ASHLAND INC. (0001674862) (Filer)

    1/27/26 4:30:25 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent

    CD388 is an investigational long-acting, strain-agnostic antiviral agent currently in Phase 3, designed to prevent influenza infection in individuals at higher risk of influenza complications Acquisition aligns with Merck's science-led business development strategy, diversifying and expanding the company's pipeline Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (NASDAQ:CDTX) ("Cidara"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a tot

    11/14/25 6:45:00 AM ET
    $CDTX
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ashland announces executive leadership changes

    WILMINGTON, Del., May 05, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that Kevin Willis, senior vice president and chief financial officer, has decided to leave Ashland to pursue another opportunity. His last day with the company will be May 16, 2025. Willis joined Ashland in 1987 as an associate auditor in the internal audit department. He has served in various management positions of increasing responsibility, including leading teams on major projects in the business services, information technology, accounting and finance areas. Willis' departure is not the result of any disagreement with the company related to its financial statements, internal control over finan

    5/5/25 5:00:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    Financials

    Live finance-specific insights

    View All

    Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline

    Reports Strength in Oncology and Animal Health, Plus Increasing Contributions From WINREVAIR and CAPVAXIVE Fourth-Quarter Worldwide Sales Were $16.4 Billion (5% Growth; 4% Growth ex-FX) Fourth-Quarter GAAP EPS Was $1.19; Non-GAAP EPS Was $2.04; GAAP and Non-GAAP EPS Include a Charge of $0.05 per Share for the Acquisition of MK-8690 Sole Global Rights Full-Year Worldwide Sales Were $65.0 Billion (1% Growth; 2% Growth ex-FX) KEYTRUDA/KEYTRUDA QLEX Sales Were $31.7 Billion (7% Growth Both Nominally and ex-FX); Includes KEYTRUDA QLEX Sales of $40 Million WINREVAIR Sales Were $1.4 Billion CAPVAXIVE Sales Were $759 Million GARDASIL/GARDASIL 9 Sales Were $5.2 Billion (39% Decli

    2/3/26 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ashland reports first quarter fiscal 2026 results and narrows full-year outlook

    Sales of $386 million, down five percent from the prior-year quarterPreviously announced Avoca divestiture reduced overall sales by approximately $10 million or two percent versus the prior-year quarter; excluding the Avoca divestiture, sales declined three percentLoss from continuing operations of $14 million, or $(0.30) per diluted shareAdjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $12 million, or $0.26 per diluted shareNet loss of $12 million, or $(0.26) per diluted shareAdjusted EBITDA of $58 million, down five percent from the prior-year quarter, with the Avoca divestiture contributing to a two percent or $1 million decline; excluding the Avoca

    2/2/26 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Merck Announces Second-Quarter 2026 Dividend

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.85 per share of the company's common stock for the second quarter of 2026. Payment will be made on April 7, 2026, to shareholders of record at the close of business on March 16, 2026. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten

    1/27/26 3:07:00 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ashland Inc.

    SC 13G - ASHLAND INC. (0001674862) (Subject)

    11/12/24 11:54:03 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Ashland Inc.

    SC 13G/A - ASHLAND INC. (0001674862) (Subject)

    7/10/24 1:14:41 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SC 13D/A filed by Ashland Inc. (Amendment)

    SC 13D/A - ASHLAND INC. (0001674862) (Subject)

    4/25/24 4:15:12 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary